Advertisement
Screener

aTYR PHARMA INC (ATYR) Contract Liability (Deferred Revenue)

2.8 / 5 stars · 68/120 Roast Me

aTYR PHARMA INC Contract Liability (Deferred Revenue)

aTYR PHARMA INC (ATYR) had Contract Liability (Deferred Revenue) of $53.00 thousand as of 2020-09-30, per its 10-Q filed 2020-11-13.

Discontinued › Balance Sheet › Liabilities › Liabilities, Current

us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2021-03-24

  • 2020-09-30: Contract with Customer, Liability, Current $53.00K.
  • 2020-06-30: Contract with Customer, Liability, Current $201.00K.
  • 2020-03-31: Contract with Customer, Liability, Current $143.00K.
  • 2019-12-31: Contract with Customer, Liability, Current $208.00K.
Period endContract with Customer, Liability, Current
2020-09-30$53.00K
10-Q · filed 2020-11-13
2020-06-30$201.00K
10-Q · filed 2020-08-13
2020-03-31$143.00K
10-Q · filed 2020-05-12
2019-12-31$208.00K
10-K · filed 2021-03-24
2019-09-30$352.00K
10-Q · filed 2019-11-14
2019-06-30$536.00K
10-Q · filed 2019-08-14
2019-03-31$630.00K
10-Q · filed 2019-05-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
Quince Therapeutics, Inc. (QNCX)United States$0.031B
CEL SCI CORP (CVM)United States$0.030B-0.81
Scilex Holding Co (SCLX)United States$0.042B-0.14
Metagenomi Therapeutics, Inc. (MGX)United States$0.044B-0.48
Estrella Immunopharma, Inc. (ESLA)United States$0.020B
LeonaBio, Inc. (LONA)United States$0.047B-0.61
Jasper Therapeutics, Inc. (JSPR)United States$0.020B-0.37
Instil Bio, Inc. (TIL)United States$0.048B-1.73
Tevogen Inc. (TVGN)United States$0.049B
BioCardia, Inc. (BCDA)United States$0.016B